Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate CHI-X - 09/18 07:02:55 am
436.375 DKK   +0.28%
09/14European healthcare stocks hit by Trump drug order
RE
09/14NOVO NORDISK A/S : – Share repurchase programme
AQ
09/01NOVO NORDISK A/S : insulin production line launches in Iran
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVO NORDISK : Goldman Sachs keeps its Buy rating

share with twitter share with LinkedIn share with facebook
08/11/2020 | 01:44am EDT

In a research note, Goldman Sachs analyst Jonathan Kownator has maintained his recommendation on the stock with a Buy rating. The target price is lowered from DKK 475 to DKK 484.

Stocks mentioned in the article
ChangeLast1st jan.
NOVO NORDISK A/S 0.38% 436.65 Delayed Quote.12.54%
THE GOLDMAN SACHS GROUP, INC. -2.92% 194.83 Delayed Quote.-15.27%

© MarketScreener with dpa-AFX Analyser 2020
share with twitter share with LinkedIn share with facebook
All news about NOVO NORDISK A/S
09/14European healthcare stocks hit by Trump drug order
RE
09/14NOVO NORDISK A/S : – Share repurchase programme
AQ
09/01NOVO NORDISK A/S : insulin production line launches in Iran
AQ
08/31NOVO NORDISK A/S : – Share repurchase programme
AQ
08/26NOVO NORDISK A/S : Disclosure of transaction data related to Novo Nordisk's shar..
PU
08/25NOVO NORDISK A/S : Karolinska Institutet, St. Erik Eye Hospital and Novo Nordisk..
AQ
08/20NOVO NORDISK A/S : Q2 2020 conference call presentation
PU
08/20NOVO NORDISK A/S : Q2 2020 London presentation
PU
08/18NOVO NORDISK : UBS sticks Neutral
MD
08/17NOVO NORDISK A/S : Disclosure of transaction data
PU
More news
Financials
Sales 2020 128 B 20 349 M 20 349 M
Net income 2020 41 652 M 6 636 M 6 636 M
Net cash 2020 11 498 M 1 832 M 1 832 M
P/E ratio 2020 24,4x
Yield 2020 2,06%
Capitalization 1 013 B 161 B 161 B
EV / Sales 2020 7,84x
EV / Sales 2021 7,32x
Nbr of Employees 43 526
Free-Float 68,7%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 446,08 DKK
Last Close Price 435,15 DKK
Spread / Highest target 20,6%
Spread / Average Target 2,51%
Spread / Lowest Target -29,9%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S12.54%160 907
JOHNSON & JOHNSON0.89%390 711
ROCHE HOLDING AG7.37%317 035
MERCK & CO., INC.-5.84%216 427
PFIZER, INC.-6.13%204 382
NOVARTIS AG-10.48%199 714